Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Pluri Inc. addresses price instability in the coffee industry highlighted in the International Coffee Organization's 2024 Market Report by introducing cell-based coffee production, offering a sustainable and innovative solution.
  • None.
  • None.

The recent publication by the International Coffee Organization underscores significant concerns about price instability in the coffee market, primarily due to erratic weather patterns. This presents a substantial risk for businesses within the coffee industry, from growers to retailers, as well as for investors. The report's findings could lead to increased costs for coffee production, which may be passed on to consumers, potentially reducing demand.

Furthermore, the report's implications extend to global supply chains. Companies may face disruptions and those without diversified sourcing strategies could experience severe setbacks. Investors should monitor companies with exposure to coffee commodities for risk management strategies addressing these concerns. The shift towards lab-grown coffee, like Pluri Inc.'s initiative, could be a game-changer by offering a more stable alternative to traditional coffee production, potentially leading to a reallocation of market shares within the industry.

Pluri Inc.'s approach to coffee production using cell-based technology is a significant stride in addressing environmental concerns. By potentially reducing water usage by 98% and farmland usage by 95%, this innovation could lead to a paradigm shift in agricultural practices. The environmental benefits are clear, as traditional coffee farming is often associated with deforestation and high water consumption.

Investors with an interest in sustainable and responsible investments should take note of this development. It aligns with growing consumer demand for environmentally friendly products. However, it's essential to scrutinize the scalability and consumer acceptance of cell-based coffee, as these factors will ultimately determine its success and impact on the market and the environment.

Pluri's entry into the coffee market with its cell-based coffee product represents an innovative disruption within the biotechnology and agriculture sectors. The use of cell culture technology in coffee production is a novel application and its market potential is vast, given the size of the global coffee industry. Investors should evaluate Pluri's technological capabilities, intellectual property and ability to scale production.

It is important to assess the regulatory landscape for such novel food products, as it will affect the speed at which they can reach the market. The cost-effectiveness of the production process and the product's price point in comparison to traditional coffee will also be decisive factors in its adoption. Investors should consider these aspects when evaluating Pluri's potential impact on the coffee industry and its stock valuation.

  • International Coffee Organization (ICO) Market Report published on March 7, 2024 highlights alarming price instability challenging the coffee industry
  • According to the report, adverse weather conditions, first noted in 2022 and continuing into 2023, will have a negative impact on the outlook for coffee in 2024
  • Pluri’s cell-based coffee’s innovative process mimics nature without exploiting it, ensuring consistent quality and high yields, addressing challenges listed in the report

HAIFA, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today addressed the price volatility challenge detailed in the International Coffee Organization’s (ICO) 2024 Market Report (the “Report”) According to the Report, one of the factors creating price volatility is the erratic weather conditions across the globe; from frost in Brazil in 2021 to the El Niño phenomenon expected to worsen heatwaves in Vietnam in 2024. Price instability and cost increases will impact coffee drinkers worldwide, as more than 2 billion cups of coffee are drunk each day, 400 million of them by Americans.

Pluri’s cell-based coffee aims to reduce price instability by moving coffee production into the lab, eliminating the effect of climate change and adverse weather conditions. Pluri recently announced the launch of its cell-based coffee, its proprietary cultured coffee product business, part of its PluriAgtech vertical, addressing the $130 billion coffee industry. The Company’s cell production method grows coffee quickly and reliably in an environmentally sustainable, cost-effective, tightly controlled fully automated manufacturing process that is highly scalable. Pluri’s cell-based coffee is estimated to slash water usage by 98% throughout the entire supply chain and reduce farmland usage by 95% as compared to traditional growing methods.

To learn more about Pluri’s coffee see the recent article titled “Cell-Based Coffee Future-Proofs World’s Favorite Brew” in the leading peer-reviewed journal Nature Biotechnology.

“Pluri’s proprietary method for producing coffee aims to produce a better product with regards to taste, texture, scent, and sustainability,” stated Pluri’s CEO and President Yaky Yanay. “Our solution can help the industry produce coffee in a stable and controlled environment, ensuring consistent availability, price stability and saving everyone’s favorite beverage.”

Learn more about Pluri's innovative cell-based coffee technology by visiting our website.

About Pluri Inc.

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech, agtech and biologics and offers CDMO services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production. To learn more, visit us at or follow Pluri on LinkedIn and X (formerly known as Twitter).

Safe Harbor Statement

This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the potential benefits of its cell-based coffee and that its solution can help the industry produce coffee in a stable and controlled environment, ensuring consistent availability and price stability. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri's reports filed from time to time with the Securities and Exchange Commission.

Media Contacts


Israel Media: Shachar Yental at

U.S. Media: Jessica Daitch at / Madeline Weirman at


How does Pluri address the price instability challenge in the coffee industry?

Pluri addresses price instability by introducing cell-based coffee production, moving coffee production into the lab to eliminate the impact of climate change and adverse weather conditions.

What are the benefits of Pluri's cell-based coffee production method?

Pluri's cell-based coffee production method is estimated to slash water usage by 98% and reduce farmland usage by 95% compared to traditional growing methods.

What industry does Pluri operate in?

Pluri operates in the biotechnology sector, transforming cells into solutions that promote global wellbeing and sustainability.

What is Pluri's ticker symbol?

Pluri's ticker symbol is PLUR.

Pluri Inc.


PLUR Rankings

PLUR Latest News

PLUR Stock Data

Biological Product (except Diagnostic) Manufacturing
United States of America

About PLUR

pluristem therapeutics inc. (nasdaqcm: psti, tase: psti/pltr) is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3d) technology platform to develop cell therapies for conditions such as inflammation, ischemia, hematological disorders, or exposure to radiation. pluristem’s placental expanded (plx) cells are placenta-derived, mesenchymal-like adherent stromal cells that are designed to be administered to patients without the need for tissue or genetic matching. these cells release soluble biomolecules, such as cytokines, chemokines and growth factors, which act in a paracrine or endocrine manner to facilitate healing of damaged tissues by stimulating the body’s own regenerative mechanisms. the company’s proprietary, 3d expansion technology can be used to grow plx cells in mass quantities with batch-to-batch consistency at pluristem’s fda, ema and pmda-approved, state-of-the art manufacturing facility. pluristem’s first product candi